Nivolumab,Ipilimumab,Pazopanib,Sunitinib
BMS,Novartis,Pfizer
['nivolumab', 'nemo ', 'rcc,(-irccs),(-srcc),(-urcc)', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'ipilimumab', 'nivo', 'bionikk']
overall survival and efficacy results of second-line treatment in patients with #mccrcc treated in the randomized phase ii #bionikk trial. presented by yann-alexandre vano, md . #gu23 coverage &gt; 
Largest global online community of #urological medical professionals & patients. #bladdercancer #menshealth #prostatecancer #kidneycancer #Urology